

**27th Annual Report
2016-2017**

*Innovating & Marching ahead
with Biologicals*



TRANSGENE
BIOTEK LIMITED
INNOVATING. FOR LIFE.



BOARD OF DIRECTORS

Dr. K. Koteswara Rao	Chairman & Managing Director
Dr. Puranik Sarang Subhash	Director
Mr Shyam Shankar Das	Director
Mrs. Sujana Kadiam	Director

Registered Office

Plot Nos. 68,69 & 70
Anrich Industrial Area,
IDA Bollaram,
Medak District. T.S. - 502 325.

Factory

Plot Nos. 68,69 & 70
Anrich Industrial Area,
IDA Bollaram,
Medak District. T.S. - 502 325.

Auditors

M/s. Gopal & Rajan
G4, Sterling Majestic Apts.,
Walker's Town,
Padmarao Nagar,
Secunderabad - 500 025.

Bankers

Union Bank of India

Jubilee Hills Branch,
Hyderabad.

Share Transfer Agents

M/s Bigshare Services Pvt. Ltd.

306, 3rd Floor, Right Wing,
Amrutha Vide, Bhavan Road,
Somajiguda, Hyderabad - 500 082.

TWENTY SIXTH ANNUAL REPORT 2016-17

NOTICE

Notice is hereby given that the Twenty seventh (27th) Annual General Meeting of the Members of M/s. TRANSGESNE BIOTEK LIMITED will be held on Friday, the 29th September, 2017 at 11.00 Hours at the Board Room Hall (1st Floor) of Hotel a Lounge, (above Laxmi Hyundai show room) Madinaguda, Miyapur, Hyderabad (Tel No: 040-65553456 or 65453456), Sangareddy District, Telangana State, to transact the following business.

ORDINARY BUSINESS:

1. ADOPTION OF AUDITED ACCOUNTS AND REPORTS

To receive, consider and adopt the Balance Sheet as at 31st March, 2017 including the audited Balance Sheet as at March 31, 2017, the Profit and Loss Account for the year ended as on that date, Directors' Report and Auditors' Report thereon.

2. RE-APPOINTMENT OF DIRECTOR

To appoint a Director in place of Dr Puranik Sarang Subhash who retires by rotation and being eligible offers himself for re-appointment.

3. APPOINTMENT OF AUDITORS

To consider and if thought fit to pass the following resolution with or without modification(s) as Ordinary Resolution:

“RESOLVED THAT pursuant to Section 139, 142 and other applicable provisions, if any, of the Companies Act, 2013 read with rules made thereunder (including any statutory modification (s) or re-enactment (s) thereof, for the time being in force), the Company hereby appointing M/s. Lakshmi & Associates, Chartered Accountants as Statutory Auditors of the Company from the conclusion of this 27th Annual General Meeting until the conclusion of the 28th Annual General Meeting of the Company to be held in the year 2018 to examine and audit the accounts of the Company at such remuneration to be fixed by the Board of Directors in consultation with the Auditors.”

SPECIAL BUSINESS

4. RE-APPOINTMENT OF DR. K. KOTESWARA RAO AS CHAIRMAN & MANAGING DIRECTOR OF THE COMPANY.

Re-appointment of Dr K. Koteswara Rao (DIN No: 02287235) as Chairman and Managing Director of the Company.



EXPLANATORY STATEMENT PURSUANT TO SECTION 102 OF THE COMPANIES ACT, 2013.

Because of several pending issues remaining unresolved from the earlier period requiring constant inputs from Dr. K. Koteswara Rao for initiating and taking appropriate actions as deemed necessary in a timely manner apart from several ongoing regulatory and commercial developments, the Board of Directors recommend that it is important to maintain continuity of the top management of company at this critical juncture, hence the Board recommends that Dr. K. Koteswara Rao, who is well past the age of 70 years, continues to function as Managing Director of the company for another 1 (one) year.

In this regard to consider and, if thought fit, to pass, with or without modification(s), the following resolution as a SPECIAL RESOLUTION:

“RESOLVED THAT pursuant to the provisions of Sections 196, 197, 198, and all other applicable provisions of the Companies Act, 2013 and the rules made there under (including any statutory modification(s) or re-enactment thereof for the time being in force), read with Schedule V to the Companies Act, 2013 and subject to such permissions, consents and approvals from various authorities as may be required and subject to such conditions, if any, that may be imposed by any authority while granting their permissions, consents and approvals, the approval of shareholders of the Company be and is hereby accorded for re-appointment of Dr. K. Koteswara Rao (DIN: 02287235) as Chairman & Managing Director of the Company for a period of 1 (one) year without any remuneration and on the such terms and conditions set out below in the explanatory statement annexed hereto which shall be deemed to form part hereof.

RESOLVED FURTHER THAT the Board of Directors and/or Company Secretary of the Company be and is hereby authorized to do all such acts, deeds, matters and things they may consider necessary, expedient or desirable in order to give effect to this resolution or otherwise considered by them in the best interest of the Company.”

5. ASSIGNMENT OF LICENSE TO OLYMPUS BIOSOLUTIONS FOR MARKETING OF ORAL PROTEIN DELIVERY PLATFORM.

Olympus Biosolutions (or such name as may be given) will be remunerated Solely upon successful closing of a Licensing/Sale/Investment/Transaction related to our Oral Protein Delivery Platform.

Explanation

Our project on Oral delivery of Insulin (amongst other proteins and peptides) has been in the making for more than 10 years at Transgene. However, although the company has been scientifically successfully in the development of this platform technology, insufficient progress has been made towards commercialization of this product. At this juncture, with the technology sufficient poised for 3rd Party review for potential Out-Licensing/Sale/Investment, we believe that Olympus BioSolutions is an ideal partner to help us forge ahead with our goal to Out-License/Sell/Partner this Game-changing technology. Olympus is an organization that consists of individuals who possess decades of experience, knowledge

TWENTY SIXTH ANNUAL REPORT 2016-17

and know-how in the transaction advisory and investment banking space. The Management believes that their expertise and networks will provide a much-needed boost in our search for a technology Partner. Any remuneration/fees to be paid to Olympus will only be accrued from successful consummation of a transaction. Success fees to be paid to Olympus could range upto 25% depending on the costs involved in the transaction, and the eventual transaction itself. It should be declared that Mr Laxmidhar Rao, son of Managing Director Dr K Koteswara Rao, an MBA from Oxford University, UK, and an ex-investment banker from the City of London is a partner in Olympus and will play role in these Partnering activities and efforts from Olympus.

As Mr. K. Laxmidhar is the son of Dr. K. Koteswara Rao, Chairman and Managing Director of the company, in this regard it is considered and, if thought fit to pass, with or without modification(s), the following resolution as a SPECIAL RESOLUTION:

"RESOLVED THAT pursuant to applicable provisions of the Companies Act, 2013 and the provisions of Clause 49 VII of the Listing Agreement (including any statutory modification(s) or re-enactment thereof, for the time being in force, approval/ratification of the shareholders be and is hereby accorded to the Company for entering into a transaction and agreement with Olympus Biosolutions wherein Mr. Laxmidhar K. being a 'Related Party' as defined under Section 2 (76) of the Companies Act, 2013 and Clause 49 VII of the Listing Agreement, pursuant to an Agreement to be entered into by Transgene Biotek Ltd with Olympus Biosolutions wherein for undertaking, organizing and concluding a Technology Out-Licensing deal and agreement with a third party with a payable remuneration not exceeding 25% of the amount received by Transgene Biotek Ltd from the in-licensing third party.

RESOLVED FURTHER THAT the Board of Directors of the Company be and is hereby authorised to do or cause to be done all such acts, deeds and things, settle any queries, difficulties, doubts that may arise with regard to any transactions with the related party and in-licensing third party, make such changes to the terms and conditions as may be considered necessary, expedient or desirable and execute such addendum agreements, documents and writings and to make such filings as may be necessary or desirable, in order to give effect to this Resolution as may be deemed necessary in the best interest of the Company."

By the Order Of the Board
For **TRANSGENE BIOTEK LIMITED**

Sd/-

Dr. K. KOTESWARA RAO
CHAIRMAN & MANAGING DIRECTOR

PLACE: HYDERABAD
DATE: 14.08.2017



NOTES

1. A MEMBER ENTITLED TO ATTEND AND VOTE AT THE MEETING IS ENTITLED TO APPOINT A PROXY TO ATTEND AND VOTE INSTEAD OF HIMSELF AND SUCH PROXY NEED NOT BE A MEMBER OF THE COMPANY. THE PROXIES TO BE EFFECTIVE SHOULD BE DEPOSITED AT THE REGISTERED OFFICE OF THE COMPANY NOT LATER THAN 48 HOURS BEFORE THE COMMENCEMENT OF THE MEETING.
2. The relevant details of the directors seeking appointment under Item Nos 2 as required by SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 entered into with the Stock Exchange are annexed.3. Register of members and share transfer books of the company will remain closed from 27-09-2017 to 29-09-2017 (both days inclusive). Members / Proxies should bring the attendance slips duly filled in and signed for attending the meeting.
3. Members, who are holding shares in the identical order of names in more than one folio, are requested to write to the Company to enable it to consolidate their holding in one folio.
4. As per the provisions of the Companies Act, 2013, facility for making nomination is available for Members of the Company in respect of shares held by them. The members, who wish to nominate a person, *may furnish the required details to the Company in prescribed form.*
5. The Ministry of Corporate Affairs has taken a "Green Initiative in the Corporate Governance" by allowing paperless compliances by the companies and has issued circulars stating that service of notice/documents including Annual Report can be sent by e-mail to its members. To support this green initiative of the Government in full measure, members who have not registered their e-mail addresses, so far, are requested to register their e-mail addresses. In respect of electronic holdings, with the Depository through their concerned Depository Participants and members who hold shares in physical form are requested to register the same with our RTA, Bigshare Services Pvt Ltd, 306, Right Wing, Amruta Ville, Opp Yashoda Hospital, Raj Bhavan Road, Somajiguda, Hyderabad 500082.

6. VOTING THROUGH ELECTRONIC MEANS

In compliance with the provisions of the Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Section 108 of the Companies Act, 2013 and the Rule 20 of the Companies (Management and Administration) Rules, 2014, the company is pleased to provide members facility to exercise their votes for all the resolutions detailed in the Notice of the 27th Annual Report of the company and the business may be transacted through e-voting. The company has engaged the services of Central Depository Services Limited (CDSL) as the authorized agency to provide the e-voting facility.

The instructions for shareholders voting electronically are as under:

Mr. M V R Murthy, Membership No.F8522 and CP No. 9552, Practicing Company Secretary is appointed as scrutinizer to conduct E-voting.

TWENTY SIXTH ANNUAL REPORT 2016-17

STEPS FOR E-VOTING

7. The voting period begins on 26th September, 2017 at 9.00 a.m. and ends on 28th September, 2017 at 5.00 P.M. During this period shareholders' of the Company holding shares either in physical form or in dematerialized form, as on the cut-off date (record date) of 22nd September, 2017 may cast their vote electronically. The e-voting module shall be disabled by CDSL for voting thereafter.
8. The voting rights of members shall be in proportion to their shares of the paid up equity share capital of the company as on 22nd September, 2017
9. The shareholders should log on to the e-voting website www.evotingindia.com.

Click on Shareholders.

- i) Now enter your User ID:
 - a. For CDSL: 16 digits beneficiary ID,
 - b. For NSDL: 8 Character DP ID followed by 8 Digits Client ID,
 - c. Members holding shares in Physical Form should enter Folio Number registered with the Company.
- ii) Next enter the image verification as displayed and Click on Login.
- iii) If you are holding shares in demat form and had logged on to www.evotingindia.com and voted on an earlier voting of any company, then your existing password is to be used.
- iv) If you are a first time user follow the steps given below:

For Members holding shares in Demat Form and Physical Form

PAN	<ul style="list-style-type: none">Enter your 10 digit alpha-numeric PAN issued by Income Tax Department (Applicable for both demat shareholders as well as physical shareholders)
	<ul style="list-style-type: none">Members who have not updated their PAN with the Company/Depository Participant are requested to use the first two letters of their name and the 8 digits of the sequence number in the PAN field.
	<ul style="list-style-type: none">In case the sequence number is less than 8 digits enter the applicable number of 0's before the number after the first two characters of the name in CAPITAL letters. Eg. If your name is Ramesh Kumar with sequence number 1 then enter RA00000001 in the PAN field.
DOB	<ul style="list-style-type: none">Enter the Date of Birth as recorded in your demat account or in the company records for the said demat account or folio in dd/mm/yyyy format.
Dividend Bank Details	<p>Enter the Dividend Bank Details as recorded in your demat account or in the Company records for the said demat account or folio.</p> <ul style="list-style-type: none">Please enter the DOB or Dividend Bank Details in order to login. If the details are not recorded with the depository or company please enter the member id / folio number in the Dividend Bank details field as mentioned in instruction (v).



- (vii) After entering these details appropriately, click on “SUBMIT” tab.
- (viii) Members holding shares in physical form will then directly reach the Company selection screen. However, members holding shares in demat form will now reach ‘Password Creation’ menu wherein they are required to mandatorily enter their login password in the new password field. Kindly note that this password is to be also used by the demat holders for voting for resolutions of any other company on which they are eligible to vote, provided that company opts for e-voting through CDSL platform. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential.
- (ix) For Members holding shares in physical form, the details can be used only for e-voting on the resolutions contained in this Notice.
- (x) Click on the EVSN No (**170906010**) for the relevant **TRANSGENE BIOTEK LIMITED** on which you choose to vote.
- (xi) On the voting page, you will see “RESOLUTION DESCRIPTION” and against the same the option “YES/NO” for voting. Select the option YES or NO as desired. The option YES implies that you assent to the Resolution and option NO implies that you dissent to the Resolution.
- (xii) Click on the “RESOLUTIONS FILE LINK” if you wish to view the entire Resolution details.
- (xiii) After selecting the resolution you have decided to vote on, click on “SUBMIT”. A confirmation box will be displayed. If you wish to confirm your vote, click on “OK”, else to change your vote, click on “CANCEL” and accordingly modify your vote.
- (xiv) Once you “CONFIRM” your vote on the resolution, you will not be allowed to modify your vote.
- (xv) You can also take out print of the voting done by you by clicking on “Click here to print” option on the Voting page.
- (xvi) If Demat account holder has forgotten the same password then Enter the User ID and the image verification code and click on Forgot Password & enter the details as prompted by the system.
- (xvii) Note for Non-Individual Shareholders & Custodians:
 - Non-Individual shareholders (i.e. other than Individuals, HUF, NRI etc.) and Custodians are required to log on to www.evotingindia.com and register themselves as Corporates and Custodians respectively.
 - A scanned copy of the Registration Form bearing the stamp and sign of the entity should be emailed to helpdesk.evoting@cdslindia.com.
 - After receiving the login details they have to create compliance user should be created using the admin login and password. The Compliance user would be able to link the account(s) for which they wish to vote on.
 - A scanned copy of the Board Resolution and Power of Attorney (POA) which they have issued in favour of the Custodian, if any, should be uploaded in PDF format in the system for the scrutinizer to verify the same.
- (xviii) In case you have any queries or issues regarding e-voting, you may refer the Frequently Asked Questions (“FAQs”) and e-voting manual available at www.evotingindia.com under help section or write an email to helpdesk.evoting@cdslindia.com.

TWENTY SIXTH ANNUAL REPORT 2016-17

Information required to be furnished under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for directors seeking appointment/reappointment in forthcoming annual general meeting:

(i)

Name of Director	Mr Sarang Subhash Puranik
Date of Birth	30/07/1979
Date of Appointment	31/12/2014
Qualification	Ph. D
Expertise Microbiology, Immunology & Nanobioscience	
Other directorship	None
Chairman/Members of the Committee in other Companies	None
No of shares held in the Company	None

(ii)

Name of Director	Ms. Sujana Kadium
Date of Birth	06/02/1983
Date of Appointment	17/04/2015
Qualification	Post Graduate
Expertise HR Professional	
Other directorship	PFL INFOTECH LIMITED
CIN : L72200TG1993PLC007005	
Chairman/Members of the Committee in other Companies	Nil
No of shares held in the Company	Nil

(iii)

Name of Director	Dr. K. Koteswara Rao
Date of Birth	11/10/1942
Date of Appointment	30/09/2016
Qualification	M.B.B.S., MBIM
Expertise Medical Practice and Clinical Studies	
Other directorship	None
Chairman/Members of the Committee in other Companies	None
No of shares held in the Company	15,211,902

BY ORDER OF THE BOARD

Date : 14-08-2017
Place: Hyderabad

Sd/-
DR K KOTESWARA RAO
CHAIRMAN & MANAGING DIRECTOR

**DIRECTORS REPORT**

Dear Shareholders

Your Directors submit to you the 27th Annual Report on the business & operations of the Company and Audited Statement of Accounts for the year ended 31st March, 2017 along with the Auditor's Report thereon.

Financial Results

(Rs. In Lakhs)

Particulars	2016-2017	2015- 2016
Total Income	76.30	34.98
Operational, Administration and other expenses	284.18	131.28
Gross Operating Profit	(207.88)	(96.29)
Interest and Financial Charges	7.23	7.31
Forex Gain/Loss	0.00	0.00
Depreciation	1752.71	2050.23
Profit before Tax/Loss	(1967.83)	(2153.84)
Provision for Tax	0.00	0.00
Net Profit/Loss	(1967.83)	(2153.84)

OPERATIONS

The total turnover of the company for the year ended 31st March, 2017 amounted to Rs. 76.30 Lakhs as against Rs. 34.98 Lakhs in the previous year. The company incurred a net Loss of Rs. 1967.83 Lakhs for the year as against a loss of Rs. 2153.84 Lakhs in the previous year. As can be noticed, the management started the exercise to revise books of accounts and has written off certain accounts after following the standard accounting policies of India and in consultation with the auditors.

AUDITORS' COMMENTS

The subsidiary of the company Transgene Biotech HK Ltd has not been operating for the entire year as was the case last year too, with no auditors being appointed hence no audit report has been received by the management. Therefore, the auditors are unable to express opinion on this.

GDR ISSUE

One of the major hurdles faced by the company during the last 5-6 years is the adverse impact as a result of GDR fraud perpetrated. As a consequence to that GDR episode, an ad interim order was passed by SEBI on 20 November 2014 which was subsequently reconfirmed on March 9, 2016. The management filed appeals at SAT on behalf of all the named persons in the SEBI order. SAT in their order dated 17th August 2017 presided over by the Hon'ble Justice J. P. Devadhar has disposed off the appeals pronouncing **"Accordingly, without going into the merits, we dispose of these appeals by directing SEBI to complete the investigation by December, 2017 and if deemed fit issue show-cause notice by 31st December, 2017. Before issuing the show-**